COMMUNIQUÉS West-GlobeNewswire
-
Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry
19/08/2024 -
Spectral AI Announces Podium Presentation at BBA / ISBI Joint Conference Assessing Burn Wound Severity Using Multispectral Imaging and Artificial Intelligence
19/08/2024 -
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
19/08/2024 -
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
19/08/2024 -
Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain
19/08/2024 -
Auron Presents Preclinical Data at American Chemical Society Annual Meeting
19/08/2024 -
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
19/08/2024 -
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19/08/2024 -
Assure Announces Further Extension of Exchange Offer Relating to its Convertible Notes
19/08/2024 -
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19/08/2024 -
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/08/2024 -
Calibre Scientific Acquires Industrial Glassware, a U.S. Manufacturer and Provider of Laboratory Supplies and Consumables
19/08/2024 -
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
19/08/2024 -
Kraig Biocraft Laboratories Successfully Completes Third Commercial Spider Silk Production Cycle
19/08/2024 -
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
19/08/2024 -
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
19/08/2024 -
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
19/08/2024 -
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
17/08/2024 -
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
17/08/2024
Pages